Skip to main content

Advertisement

ADVERTISEMENT

First Report

When patients with gBRCA1/2mut HER2− advanced breast cancer switched from olaparib to talazoparib, a reduction in costs for US commercial health plans was observed.

Advertisement

Recent data shows that ixekizumab limits out-of-pocket spending for psoriatic arthritis treatment, despite associated higher pharmacy costs.
According to a study focused on real world data, adults with severe eosinophilic asthma experienced symptomatic improvements and decreased health care resource utilization when treated wi...
Treatment with ibrutinib was associated with lower outpatient services compared with traditional chemoimmunotherapy, according to researchers of a study comparing overall health care util...

Advertisement

First Report
11/08/2019
Robert Greer, RPh, BCOP, senior director of clinical strategy and programs at Magellan Rx Management, discusses the use of ibrutinib compared with traditional immunochemotherapy, and small molecule inhibitors in the treatment of chronic...
Robert Greer, RPh, BCOP, senior director of clinical strategy and programs at Magellan Rx Management, discusses the use of ibrutinib compared with traditional immunochemotherapy, and small molecule inhibitors in the treatment of chronic...
Robert Greer, RPh, BCOP, senior...
11/08/2019
First Report Managed Care

Advertisement